Home » News » July 2020

July, 2020

Telix Pharmaceuticals reports receipt of $11.4M Refundable R&D Tax Offset

July 27th, 2020

Melbourne-based Telix Pharmaceuticals Ltd has reported during the week receipt of an $11.4M Refundable R&D Tax Offset in respect of activity conducted during the YE 31 December 2019. This would be one of the largest single-year Refundable offset receipts in the history of the R&D Tax Incentive and infers an R&D Expenditure of approximately $26M AUD. The underlying activity relates to the development of diagnostic and therapeutic products using molecularly targeted radiation. Receipt of a tax offset of this magnitude […]

Read More

R&D Tax Incentive Advocate CSL Rapidly Adapts R&D Effort to focus on COVID-19

April 14th, 2020

The Australian newspaper digested the ASX announcement of CSL late last week and detailed how the company, which recently has overtaken CBA as the largest cap stock on the ASX, has rapidly adapted its R&D Effort in response to the COVID-19 situation. The article reports: The health challenges presented by COVID-19 have led to delays in the ability to conduct clinical trials and to progress candidates within the company’s existing pipeline; CSL remains on track to invest 10% of its […]

Read More

Categories

Archives